Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 Single Ascending Dose in Healthy Males
NCT03007810Phase 1Completed
- Sponsor
- Tianjin Hemay Biotech
- Start
- Dec 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing Hemay005 with Placebo (2 arms). Primary endpoint: Number of adverse events and serious adverse events. Started Dec 2016; status: completed.
02
Drugs
mufemilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03007810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03007810.